Igalmi (Dexmedetomidine sublingual film) can be hard to find. Learn why availability is limited in 2026, what's causing the issue, and how to locate it.
If you or a loved one has been prescribed Igalmi (Dexmedetomidine sublingual film), you may have run into a frustrating problem: it's not easy to find. Unlike common medications that line pharmacy shelves across the country, Igalmi occupies a unique niche in the pharmaceutical world — and that niche comes with real availability challenges.
In this guide, we'll break down what Igalmi is, why it can be so difficult to locate, and what steps you can take to find it when you need it most.
Igalmi is a prescription medication containing Dexmedetomidine, an alpha-2 adrenergic receptor agonist. It was approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Unlike many psychiatric medications you take daily at home, Igalmi is a sublingual film — a thin strip placed under the tongue or behind the lower lip — that dissolves and works quickly to calm agitation.
Igalmi is typically administered in a clinical setting under healthcare provider supervision. The provider monitors vital signs like blood pressure and heart rate after the dose is given. It comes in two strengths: 120 mcg and 180 mcg, and the maximum total daily dose is 360 mcg.
There are several reasons Igalmi can be difficult to locate in 2026:
Igalmi isn't the kind of medication you pick up at your local CVS or Walgreens alongside a bottle of ibuprofen. Because it's designed for acute agitation episodes and must be given under medical supervision, it's primarily stocked in hospitals, psychiatric facilities, emergency departments, and crisis stabilization units. Most retail pharmacies simply don't carry it.
Igalmi is made exclusively by BioXcel Therapeutics. With only one company producing the drug and no generic version available, the supply chain has a single point of vulnerability. Any disruption in manufacturing, packaging, or distribution can ripple through the entire market.
As of 2026, there is no generic version of Igalmi (Dexmedetomidine sublingual film). While the active ingredient Dexmedetomidine is available in IV form (marketed as Precedex), the sublingual film formulation is unique to Igalmi. This means there's no cheaper, more widely available substitute in the same dosage form.
Igalmi is indicated for a specific patient population — adults experiencing acute agitation from schizophrenia or bipolar disorder. Because the market is relatively small compared to blockbuster drugs, pharmacies and distributors may not prioritize stocking it, especially outside of major hospital systems.
If you or a healthcare provider is looking for Igalmi, here are some practical steps:
For more tips, check out our guide on how to find Igalmi in stock near you.
If you can't find Igalmi, there are other medications used to treat acute agitation that your provider may consider. These include Haloperidol (Haldol), Olanzapine (Zyprexa), Lorazepam (Ativan), and Ziprasidone (Geodon). Each has a different mechanism and side effect profile, so it's important to discuss options with your healthcare team. Learn more in our article on alternatives to Igalmi.
Igalmi is a valuable treatment option for acute agitation in adults with schizophrenia or bipolar disorder, but its specialty nature, single manufacturer, and clinical-setting requirements make it harder to find than most medications. The good news is that tools like Medfinder and direct outreach to the manufacturer can help bridge the gap.
If you're struggling to find Igalmi, don't give up — and don't settle for going without treatment. Reach out to your healthcare provider, use the resources above, and explore the other articles in our Igalmi series for more help:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
